• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tolvaptan in autosomal dominant polycystic kidney disease.

作者信息

Torres Vicente E, Gansevoort Ron T, Czerwiec Frank S

出版信息

N Engl J Med. 2013 Mar 28;368(13):1259. doi: 10.1056/NEJMc1300762.

DOI:10.1056/NEJMc1300762
PMID:23534568
Abstract
摘要

相似文献

1
Tolvaptan in autosomal dominant polycystic kidney disease.托伐普坦治疗常染色体显性遗传性多囊肾病
N Engl J Med. 2013 Mar 28;368(13):1259. doi: 10.1056/NEJMc1300762.
2
Tolvaptan in autosomal dominant polycystic kidney disease.托伐普坦治疗常染色体显性遗传性多囊肾病
N Engl J Med. 2013 Mar 28;368(13):1257. doi: 10.1056/NEJMc1300762.
3
Tolvaptan in autosomal dominant polycystic kidney disease.托伐普坦治疗常染色体显性遗传性多囊肾病
N Engl J Med. 2013 Mar 28;368(13):1257-8. doi: 10.1056/NEJMc1300762.
4
Tolvaptan in autosomal dominant polycystic kidney disease.托伐普坦治疗常染色体显性遗传性多囊肾病
N Engl J Med. 2013 Mar 28;368(13):1258. doi: 10.1056/NEJMc1300762.
5
Tolvaptan in autosomal dominant polycystic kidney disease.托伐普坦用于常染色体显性多囊肾病的治疗
N Engl J Med. 2013 Mar 28;368(13):1258-9. doi: 10.1056/NEJMc1300762.
6
The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease.托伐普坦对常染色体显性遗传性多囊肾病患者肾功能的影响。
Clin Exp Nephrol. 2016 Feb;20(1):147-8. doi: 10.1007/s10157-015-1134-y. Epub 2015 Jun 13.
7
In Reply to "The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease".回应《托伐普坦对常染色体显性遗传性多囊肾病患者肾功能的影响》
Clin Exp Nephrol. 2016 Feb;20(1):149-50. doi: 10.1007/s10157-015-1154-7. Epub 2015 Nov 19.
8
Acute Response to Tolvaptan in ADPKD: A Window to Predict Long-term Efficacy?托伐普坦治疗常染色体显性多囊肾病的急性反应：预测长期疗效的窗口？
Am J Kidney Dis. 2015 Jun;65(6):811-3. doi: 10.1053/j.ajkd.2015.03.004.
9
[Tolvaptan and autosomal dominant polycystic kidney disease in the adult: let's give time to the "TEMPO" trial (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes)].托伐普坦与成人常染色体显性多囊肾病：让我们给“TEMPO”试验（托伐普坦治疗常染色体显性多囊肾病的疗效与安全性及其结果）一些时间
G Ital Nefrol. 2013 Jan-Feb;30(1).
10
Aquaretic treatment in polycystic kidney disease.多囊肾病的利水治疗
N Engl J Med. 2012 Dec 20;367(25):2440-2. doi: 10.1056/NEJMe1211857. Epub 2012 Nov 3.

引用本文的文献

1
Glucose absorption drives cystogenesis in a human organoid-on-chip model of polycystic kidney disease.在多囊肾病的人体芯片类器官模型中，葡萄糖吸收驱动囊肿形成。
Nat Commun. 2022 Dec 23;13(1):7918. doi: 10.1038/s41467-022-35537-2.
2
Effects of Suramin on Polycystic Kidney Disease in a Mouse Model of Polycystin-1 Deficiency.苏拉明对多囊蛋白-1 缺陷型小鼠多囊肾病的作用。
Int J Mol Sci. 2022 Jul 31;23(15):8499. doi: 10.3390/ijms23158499.
3
A Shared Nephroprotective Mechanism for Renin-Angiotensin-System Inhibitors, Sodium-Glucose Co-Transporter 2 Inhibitors, and Vasopressin Receptor Antagonists: Immunology Meets Hemodynamics.
肾素-血管紧张素系统抑制剂、钠-葡萄糖共转运蛋白 2 抑制剂和血管加压素受体拮抗剂的共同肾脏保护机制：免疫学与血液动力学的交汇。
Int J Mol Sci. 2022 Apr 1;23(7):3915. doi: 10.3390/ijms23073915.
4
Metabolic Reprogramming and Reconstruction: Integration of Experimental and Computational Studies to Set the Path Forward in ADPKD.代谢重编程与重构：整合实验与计算研究以推动常染色体显性多囊肾病的研究进展
Front Med (Lausanne). 2021 Nov 24;8:740087. doi: 10.3389/fmed.2021.740087. eCollection 2021.
5
Closing the gap between evidence and practice in chronic kidney disease.缩小慢性肾脏病领域证据与实践之间的差距。
Kidney Int Suppl (2011). 2017 Oct;7(2):114-121. doi: 10.1016/j.kisu.2017.07.006. Epub 2017 Sep 20.
6
Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease.叶酸偶联雷帕霉素与未偶联雷帕霉素在多囊肾病同源小鼠模型中的比较。
Am J Physiol Renal Physiol. 2018 Aug 1;315(2):F395-F405. doi: 10.1152/ajprenal.00057.2018. Epub 2018 May 2.
7
Metformin Inhibits Cyst Formation in a Zebrafish Model of Polycystin-2 Deficiency.二甲双胍抑制多囊蛋白-2 缺陷斑马鱼模型中的囊肿形成。
Sci Rep. 2017 Aug 2;7(1):7161. doi: 10.1038/s41598-017-07300-x.
8
Two autosomal dominant polycystic kidney (ADPKD) cases with advanced renal dysfunction, effectively treated with tolvaptan.两例患有晚期肾功能不全的常染色体显性遗传性多囊肾病（ADPKD）患者，使用托伐普坦治疗有效。
CEN Case Rep. 2016 May;5(1):87-90. doi: 10.1007/s13730-015-0198-6. Epub 2015 Nov 17.
9
Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease.雷帕霉素靶蛋白1（TORC1）抑制在多囊肾病早期和已发病阶段的作用
PLoS One. 2016 Oct 10;11(10):e0164193. doi: 10.1371/journal.pone.0164193. eCollection 2016.
10
The importance of total kidney volume in evaluating progression of polycystic kidney disease.总肾体积在评估多囊肾病进展中的重要性。
Nat Rev Nephrol. 2016 Nov;12(11):667-677. doi: 10.1038/nrneph.2016.135. Epub 2016 Oct 3.